PCSA · Processa Pharmaceuticals, Inc. · Executive Compensation
$1.99
-0.17 (-7.87%)
At close · Sep 9
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“Following our acquisition of Vidya and closing of the related $200 million gross private placement (from which we received net proceeds of $183.3 million) on July 30, 2026, we believe our cash and cash equivalents will be sufficient to satisfy our cash requirements over the next 12 months and beyond. This represents a material change from what we reported in our 2025 Form 10-K that disclosed substantial doubt of our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$5.56M
Shares
2.79M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| George Ng | Chief Executive Officer | $673,303 |
| Russell Skibsted | Chief Financial Officer | $566,760 |
| Sian Bigora | Former Chief Development and Regulatory Officer | $495,097 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| George Ng | Chief Executive Officer | $521,033 |
| Sian Bigora | Chief Development and Regulatory Officer | $328,251 |
| David Young | President, Research and Development and former Chief Executive Officer | $305,424 |
| Russell Skibsted | Chief Financial Officer | $244,226 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| George Ng | Chief Executive Officer | $471,091 |
| James Stanker | Chief Financial Officer | $342,624 |
| Sian Bigora | Chief Development and Regulatory Officer | $321,702 |
| David Young | President, Research and Development and former Chief Executive Officer | $186,633 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David Young | President, Research and Development and former Chief Executive Officer | $1,162,619 |
| Sian Bigora | Chief Development Officer | $1,075,592 |
| Patrick Lin | Chief Business and Strategy Officer | $1,042,778 |
| Michael Floyd | Chief Operations Officer | $1,042,411 |
| James Stanker | Chief Financial Officer | $1,040,278 |
| Wendy Guy | Chief Administrative Officer | $1,019,813 |
| George Ng | Chief Executive Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Michael Floyd | Chief Operations Officer | $706,222 |
| Sian Bigora | Chief Development Officer | $460,078 |
| Patrick Lin | Chief Business and Strategy Officer | $456,467 |
| Wendy Guy | Chief Administrative Officer | $434,807 |
| James Stanker | Chief Financial Officer | $434,512 |
| David Young | Chief Executive Officer | $434,512 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Dr. Sian Bigora | Chief Development Officer | $480,514 |
| Sian Bigora | Chief Development Officer | $480,514 |
| Patrick Lin | Chief Business and Strategy Officer | $476,228 |
| Wendy Guy | Chief Administrative Officer | $468,459 |
| James Stanker | Chief Financial Officer | $467,552 |
| David Young | Chief Executive Officer | $438,385 |
| Michael Floyd | Chief Operations Officer | $77,451 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Wendy Guy | Chief Administrative Officer | $250,702 |
| James Stanker | Chief Financial Officer | $250,702 |
| Dr. Sian Bigora | Chief Development Officer | $215,702 |
| Patrick Lin | Chief Business and Strategy Officer | $215,702 |
| David Young | Chief Executive Officer | $163,202 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Sheila Gujrathi | Board Director | Appointed | 2026-07-29 |
| Sheila Gujrathi | director | Appointed | 2026-07-29 |
Key facts
CIK
1533743
CUSIP
74275C403
13F (30d)
12 filings
12 filers
Visit website
Investor relations